Turkish OTC drug maker Gulsah failed to test its products and ingredients, and FDA blocked its U.S. imports.
What happened
FDA did not inspect the plant; instead it asked Gulsah for records on April 23, 2020 under section 704(a)(4) of the FD&C Act, which lets FDA demand records in place of an inspection. Follow-up teleconferences on July 16, 2020 and January 19, 2021 confirmed that the firm released batches shipped to the United States without testing identity and strength of the active ingredient, relied only on supplier certificates of analysis for incoming ingredient identity, and ran stability studies that did not test the active ingredient. FDA placed all of the firm's drug products on Import Alert 66-40 on March 29, 2021.
What FDA found
The firm released batches without laboratory testing to confirm each batch met its specifications, including the identity and strength of the active ingredient.
21 CFR 211.165(a)The firm did not test each incoming lot of active ingredient to confirm its identity, and did not validate that its supplier's test results were reliable.
21 CFR 211.84(d)(1) and (2)The firm's stability studies did not test the active ingredient or degradation products, so they could not show the drug stays within specification through its expiration date.
21 CFR 211.166(a)The firm's overall quality system was inadequate to meet CGMP requirements.
21 CFR parts 210 and 211
What FDA wants
FDA tells the firm to correct the violations promptly and to reply in writing within 15 working days with a plan covering testing of reserve samples, supplier qualification, stability program fixes, and an independent review of its laboratory and materials systems. FDA also strongly recommends hiring a qualified CGMP consultant to audit the whole operation.
Who should pay attention
- U.S. brands and distributors that buy OTC finished product from this contract manufacturer
- companies sourcing over-the-counter drugs made in Turkey
- quality teams that rely on supplier certificates of analysis instead of identity testing
This is a summary. Read the original letter on fda.gov.